Rheumatoid Arthritis Treatment and Biopsy Study Assessing Certolizumab Pegol (Cimzia)
Status:
Completed
Trial end date:
2012-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to conduct an Investigator-Sponsored Study to determine the
potential immunomodulatory effects of Certolizumab Pegol (CZP) treatment at the site of
disease activity (synovial lining) in subjects with rheumatoid arthritis (RA), using pre
treatment and post treatment arthroscopic synovial biopsies and ex vivo on gene expression.